Thank you to our sponsors Platinum Gold National
- Slides: 20
Thank you to our sponsors! Platinum Gold National Association of Clean Water Agencies Waste Treatment Division, King County, WA San Francisco, CA – Department of the Environment San Benito County Integrated Waste Management Hazardous Waste Management Programs, King County, WA Idaho Department of Environmental Quality King County Solid Waste, WA Los Angeles County Sanitation Districts, CA Minnesota Pollution Control California Integrated Waste Management Board Silver Santa Monica, CA Snohomish County Solid Waste District, WA City of Palo Alto, CA Environmental Compliance City of Palo Alto, CA Central Vermont Solid Waste Management City of Santa Rosa, CA Central Contra Costa Sanitary District, CA Veolia ES Med. Serve
Discussion and “Next Step” Slides: June 20 Sacramento, CA June 19 -20, 2008 © Product Stewardship Institute, Inc. June 2008
Regulatory Challenges: Issues for Discussion a) Change DEA regulations to facilitate collection of waste/unwanted pharmaceuticals from consumers b) Change the Controlled Substances Act to allow for the return of controlled substances © Product Stewardship Institute, Inc. June 2008 3
Thank you to our sponsors! Platinum Gold National Association of Clean Water Agencies Waste Treatment Division, King County, WA San Francisco, CA – Department of the Environment San Benito County Integrated Waste Management Hazardous Waste Management Programs, King County, WA Idaho Department of Environmental Quality King County Solid Waste, WA Los Angeles County Sanitation Districts, CA Minnesota Pollution Control California Integrated Waste Management Board Silver Santa Monica, CA Snohomish County Solid Waste District, WA City of Palo Alto, CA Environmental Compliance City of Palo Alto, CA Central Vermont Solid Waste Management City of Santa Rosa, CA Central Contra Costa Sanitary District, CA Veolia ES Med. Serve
Fundamental Questions q Why go through the trouble of educating consumers not to flush if there are no aquatic or human health impacts? q Is there a societal benefit to reduce the amount of waste/unwanted medications? q Is there a societal benefit to collect waste/unwanted medications once generated? q Can waste pharmaceuticals be safely disposed of in the home? © Product Stewardship Institute, Inc. June 2008 5
Potential Area of Collaboration: Joint research q Research/Study Categories – General q Quantity, type, and dollar value of waste/unwanted medications. q What are the benefits of take back programs? q What is the best available technology for destruction of waste pharmaceuticals? q What sites in the country accept waste pharmaceuticals and what are the GHG implications of transportation to these facilities? q What actions are necessary to allow hazardous © Product Stewardship Institute, Inc. waste incinerators to accept controlled substances 6 June 2008
Potential Area of Collaboration: Joint research q Research/Study Categories – Safety q Extent of abuse/diversions and accidental poisonings attributable to waste/unwanted medications in the home. q Percentage of pharmaceuticals in home storage attributable to normal use vs. waste/unwanted medications. q What is the cost to society of accidental poisonings from waste pharmaceuticals? © Product Stewardship Institute, Inc. June 2008 7
Potential Area of Collaboration: Joint research q Research/Study Categories – Environment q Percentage of pharmaceuticals entering waterways attributable to excretion vs. other pathways. q Impact on aquatic species and potential impact on human health. q To what degree are pharmaceuticals present in leachate and what risks do they represent? q Are pharmaceutical residuals found in landfill © Product Stewardship Institute, Inc. leachate, and are they expected to increase or 8 June 2008
Potential Area of Collaboration: Joint research q Research/Study Categories – Behavior and Education q What are the reasons and attitudes behind household storage and disposal practices and preferences? © Product Stewardship Institute, Inc. June 2008 9
Source Reduction: Strategies for Discussion a) Modify prescribing practices to avoid the excess purchase of medications (e. g. , samples to try, small initial doses, ID potential allergies/drug interactions up front) b) Educate consumers about taking all medications as prescribed c) Modify insurance reimbursement policies to encourage physicians to prescribe smaller doses to reach thresholds for coverage © Product Stewardship Institute, Inc. June 2008 10
Options for Disposal: Strategies for Discussion Develop consensus on best management practices for safe disposal from the home (either long-term or interim). b) Develop protocols for collecting waste medications under different scenarios, including ultimate disposal. c) Identify existing or develop demonstration programs to collect data on the relative costs, logistics, and performance of mail-back and/or collection through various location. © Product Stewardship Institute, Inc. a) June 2008 11
Options for Disposal: Strategies for Discussion d) e) f) Develop unified and consistent messaging regarding the safe and environmentally sound disposal of waste pharmaceuticals. Evaluate performance of existing and potential future collection programs. Options to reduce the cost of mail-back programs (e. g. , packaging, return distance, etc. ) © Product Stewardship Institute, Inc. June 2008 12
Options for Disposal: Strategies for Discussion g) Develop strategies for engaging retail pharmacies in collecting waste medications (e. g. , share lessons learned from retail pharmacies successfully collecting; increased consumer sales among pharmacies collecting, etc. ). © Product Stewardship Institute, Inc. June 2008 13
Next Steps n n n Designate and volunteer for workgroups Meeting Summary, Action Planning for Meeting #2 © Product Stewardship Institute, Inc. June 2008 14
Workgroup Process § Present findings/recommendations at 2 nd meeting § Develop work plan including: • Major tasks and timelines • Potential pilot opportunities • Staffing and funding requirements • Challenges, barriers © Product Stewardship Institute, Inc. June 2008 15
Other Follow-up to Meeting #1 n n Meeting summary will be distributed in draft form (comments due July 31) Action plan will be distributed in draft form (comments due July 31) Final participant list, agenda, presentations and other resources posted on PSI website Workgroup calls scheduled 16 © Product Stewardship Institute, Inc. June 2008
Thank you to for sponsoring Meeting #2
Meeting #2: Additional Stakeholders n n Pharmaceutical companies Over-the-Counter trade association National pharmacy associations Health care providers © Product Stewardship Institute, Inc. June 2008 18
Meeting #2: Suggested Agenda Items n n n Report back from work groups Federal regulatory issues Location, date, and funder of Meeting #3 © Product Stewardship Institute, Inc. June 2008 19
Meeting #2: Logistics n Location • n Washington, DC Dates • • • Sept. 8 -11 (M-Th) Oct. 6 -7 (M-T) Oct. 27 -30 (M-Th) Nov. 5 -6 (W-Th) Nov. 11 -13 (T-Th) © Product Stewardship Institute, Inc. June 2008 20
- Thank you to all our sponsors
- Customer pyramid platinum gold iron lead
- Thank you for joining our webinar
- Thank you for your listening!
- Worthy is the lamb seated on the throne
- Thank you lord you died for me
- Thank you for your attention do you have any questions
- Types of sponsors
- Essendon fc sponsors
- Calgary flames sponsors
- Laws governing medicare parts c and d
- Jeopardy sponsors
- Notre dame football sponsors
- Chapter 21 temperature heat and expansion answer key
- Platinum point owners forum
- K raheja platinum
- Amway differential bonus
- Protocomic
- Principalplatinum
- Brb millenium platinum
- Platinum vip plan